Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Current Opinion in Molecular Therapeutics|June 5, 2002
Towards optimal design of second-generation immunomodulatory oligonucleotidesEkambar R Kandimalla, Dong Yu, Sudhir Agrawal
The Prostate|January 9, 2003
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanismsHui Wang, Dong Yu, Sudhir Agrawal, et al.
Anticancer Research|May 23, 2002
Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiformeGautam Prasad, Hui Wang, Sudhir Agrawal, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2004
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combinationZhaomei Mu, Paul Hachem, Sudhir Agrawal, et al.
The Prostate|June 4, 2004
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivationZhaomei Mu, Paul Hachem, Sudhir Agrawal, et al.
International Immunopharmacology|April 15, 2005
Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in miceYukui Li, Ekambar R Kandimalla, Dong Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2003
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapyZhuo Zhang, Mao Li, Hui Wang, et al.
International Journal of Oncology|June 30, 2018
Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapyDaqing Wang, Wayne Jiang, Fugang Zhu, et al.
Annals of the New York Academy of Sciences|January 31, 2004
Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanismsHui Wang, Patsy Oliver, Zhuo Zhang, et al.
The Journal of Allergy and Clinical Immunology|June 22, 2007
Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in miceFu-Gang Zhu, Ekambar R Kandimalla, Dong Yu, et al.
Pageof 11